Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Other analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Piper Sandler restated an “overweight” rating and set a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Syros Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ SYRS opened at $0.24 on Friday. The company has a 50 day simple moving average of $1.51 and a 200 day simple moving average of $3.20. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. Syros Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $8.17. The firm has a market cap of $6.44 million, a PE ratio of -0.08 and a beta of 1.33.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the company posted ($1.35) EPS. On average, research analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Activity

In related news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the sale, the director now owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jason Haas acquired 35,363 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average cost of $1.55 per share, with a total value of $54,812.65. Following the completion of the acquisition, the chief financial officer now directly owns 59,915 shares in the company, valued at approximately $92,868.25. This represents a 144.03 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 130,707 shares of company stock worth $206,491 over the last quarter. 12.26% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals in the 3rd quarter worth approximately $34,000. Certuity LLC bought a new stake in Syros Pharmaceuticals during the second quarter worth $109,000. Acadian Asset Management LLC boosted its position in Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after purchasing an additional 163,234 shares during the period. 91.47% of the stock is owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.